Meet our senior team
Nawab Qizilbash, MBChB MRCP (UK) BSc MSc DPhil (Oxon.)
Senior Clinical Epidemiologist and Director of OXON and:
• Honorary Associate Professor, London School of Hygiene and Tropical Medicine, London University
• Clinical Observer Internal Medicine, Hospitals La Princesa and Cantoblanco, Madrid
• Member of Green Templeton College, Oxford University
• Co-author of x8 Lancet, x1 JAMA and x3 BMJ publications in epidemiology, trials and meta-analysis.
Chief editor of the textbook ‘Evidence-based Dementia Practice’ published by Blackwells, Oxford.
Co-author of chapters on ´Primary Data Collection´and ´Annex 1: Guidance on conducting systematic reviews and meta-analyses of completed comparative pharmacoepidemiological studies of safety outcomes´ In the ENCePP Guide on Methodological Standards in Pharmacoepidemiology published by EMA.
Nawab was Director, Epidemiology and Evidence-based Medicine, GSK (1997-2005); he trained under and worked with Professor Sir Richard Peto F.R.S., and was founding editor of the Cochrane Dementia Group. He also trained in general internal medicine and geriatrics under Professor Sir John Grimley Evans and was Honorary Consultant Physician at the Radcliffe Infirmary, Oxford (1997-2000), and St’s Mary’s Hospital, London (2005-2006).
He was the originator, together with Richard Peto, of the Prospective Studies Collaboration: individual participant data meta-analysis of 61 of the largest prospective cohort studies from 4 continents. Not only that, but he served on the ENCePP Steering Group for 3 years and was an expert for EMA.
Among CROs in Europe, Nawab provides biopharmaceutical sponsors with a unique combination of high quality epidemiological and clinical experience covering many therapeutic areas, to ensure the most optimal and cost-effective studies are conducted. He has sat on many Steering/Scientific committees as an expert in clinical epidemiology.
Steve Albrecht, BSc
Director of Global Strategic Development
Steve Albrecht, has over 30 years of operational experience directing observational studies, including compassionate use. He was most recently Global Head of Late Phase for Chiltern International, based in London, UK. He has been involved in directing over 150 observational studies, including large global registries and retrospective chart studies.
Lorenzo Domínguez, MD MPH
Director of Operations
Lorenzo is a medical doctor and epidemiologist with more than 20 years of experience in conducting observational studies in all major therapeutic areas in Europe.
Lorenzo previously worked as an epidemiologist at AstraZeneca and the global CRO, SGS.
Ignacio Méndez, VMD MPH
Director of Data Analytics & HEORIgnacio has more than 19 years of experience in epidemiology, health economics, patient-reported outcomes and associated statistical methodologies.
He specialises in the application and analysis of PROs and health economic measures in observational studies, safety data, and benefit-risk and decision analysis. Ignacio has previously worked at the CRO, TAIS. He was a member of the ENCePP HTA task force of the EMA. He provides advanced statistical expertise.
Marta Mariño, BSc
Marta was previously head of pharmacovigilance at Schering-Plough from 1995-2010 and has experience of all areas and phases of drug safety. She has specialised in the operational, quality and compliance aspects of safety in observational studies and patient registries.
She ensures quality and compliance of all the quantitative safety projects in OXON.
Javier Scott-Glendonwyn, BSc MSc
Director of Data Management
Javier coordinates the data management activities and the design and management of OXON’s Data Management System (DMS) comprising the electronic data capture tool (OXONeDC). He is responsible for building and managing the team, processes, policies, and structure and technology to deliver high quality data. He has over 20 years of experience in the Pharma industry, managing the development of Electronic Data Capture systems and project implementations. Furthermore, he has also worked in other technological areas such as health apps development and e-learning tools.
Our expertise is further boosted by renowned Consultants
(close collaborators on retainers) for involvement in projects as necessary
Stuart Pocock, MA PhD, Professor of Medical Statistics at the London School of Hygiene & Tropical Medicine, is an eminent medical statistician, a frequent lecturer on a variety of clinical trials issues and co-author of over 600 articles in peer-reviewed journals, (100+ NEJM/Lancet, and STROBE guideline) mainly in trials and epidemiology. He has an extensive experience with EMA/FDA and data monitoring (including Covid DISCOVERY adaptive platform trial) and devised: ´Pocock Stopping Rule´, ´Win Ratio´ and new method for ‘Individualising Benefit Risk’. Awarded the Bradford Hill Medal in 2013 by the Royal Statistical Society, Stuart has provided OXON with advice and validation of several complex analyses over the last 8 years.
CLINICAL ADR CONSULTANT
Jeffrey K. Aronson, MA DPhil FRCP HonFBPhS HonFFPM, Honorary Consultant Physician and Clinical Pharmacologist, Oxford; President Emeritus, Honorary Fellow, and Vice-President of Publications, British Pharmacological Society; Member of the Advisory Board of the British National Formulary Chairman of the British Pharmacopoeia Commission’s Expert Advisory Group on Nomenclature and former member of the NICE Appraisal Committee.
He has over 600 publications; is co-author and contributor of didactic textbooks and editor of ‘Meyler’s Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions’ and of its annual updates.